- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05047926
Prehabilitation for Stage IIIC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients
Prehabilitation for Advanced Ovarian Cancer Patients
Study Overview
Status
Conditions
Detailed Description
PRIMARY OBJECTIVES:
I. To evaluate the baseline difference in objective frailty measurements in patients with advanced ovarian cancer clinically deemed acceptable for primary surgery versus neoadjuvant chemotherapy.
II. To evaluate level of adherence and retention of patients with advanced ovarian cancer undergoing neoadjuvant chemotherapy with a prehabilitation program.
EXPLORATORY OBJECTIVE:
I. Will examine longitudinal trends and variability in function by the Short Physical Performance Battery (SPPB) over time and in response to the intervention.
OUTLINE: Patients are assigned to 1 of 3 cohorts.
COHORT 1: Patients undergoing primary surgical intervention complete surveys, undergo computed tomography (CT), and undergo collection of blood samples at baseline.
COHORT 2: Patients undergoing neoadjuvant chemotherapy complete physical activity for 30 minutes per day 3 times a week. Patients receive nutritional supplement drink up to 4.5 times daily, and complete Resilient Living program in-person or remotely over 60 minutes. Patients also undergo CT scans throughout the trial.
COHORT 3: Patients undergoing neoadjuvant chemotherapy complete physical activity remotely for 30 minutes per day 3 times a week. Patients receive nutritional supplement drink up to 4.5 times daily. Patients also undergo health coaching remotely for 60 minutes weekly, complete Resilient Living program remotely over 60 minutes, and may wear a FitBit throughout the study.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Karen P Ishitani, MSN
- Phone Number: 507-538-5355
- Email: ishitani.karen@mayo.edu
Study Contact Backup
- Name: Maureen A Lemens, BSN
- Phone Number: 507-293-1487
- Email: lemens.maureen@mayo.edu
Study Locations
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Recruiting
- Mayo Clinic in Rochester
-
Contact:
- Clinical Trials Referral Office
- Phone Number: 855-776-0015
- Email: mayocliniccancerstudies@mayo.edu
-
Principal Investigator:
- Amanika A. Kumar, M.D.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age >= 18 years old
- Diagnosed with epithelial ovarian, fallopian tube, or primary peritoneal cancer based on imaging and physician diagnosis
- Suspected Stage IIIC or IV disease based on clinician staging and imaging
- Curative intent treatment with platinum-based chemotherapy
- Planned surgical intervention at some point during treatment course
- Ability to read English
- No diagnosed severe cognitive impairment
- Ability to provide consent
- Ability to utilize technology to watch online modules for the Resilient Living Program
Exclusion Criteria:
- Hemiplegia or paraplegia
- Current pregnancy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort 1 (surveys, CT, blood samples)
Patients undergoing primary surgical intervention complete surveys, undergo CT, and undergo collection of blood samples at baseline.
|
Complete surveys
Undergo blood collection
Other Names:
Undergo CT scans
Other Names:
|
Experimental: Cohort 2 (exercise, supplement, Resilient Living)
Patients undergoing neoadjuvant chemotherapy complete physical activity for 30 minutes per day 3 times a week.
Patients receive nutritional supplement drink up to 4.5 times daily, and complete Resilient Living program in-person or remotely over 60 minutes.
Patients also undergo CT scans throughout the trial.
|
Complete surveys
Undergo CT scans
Other Names:
Given Boost or Ensure
Other Names:
Complete physical activity assignments
Complete Resilient Living program
|
Experimental: Cohort 3 (exercise, supplement, coaching, Resilient Living)
Patients undergoing neoadjuvant chemotherapy complete physical activity remotely for 30 minutes per day 3 times a week.
Patients receive nutritional supplement drink up to 4.5 times daily.
Patients also undergo health coaching remotely for 60 minutes weekly, complete Resilient Living program remotely over 60 minutes, and may wear a FitBit throughout the study.
|
Complete surveys
Undergo behavioral counseling
Other Names:
Given Boost or Ensure
Other Names:
Complete physical activity assignments
Complete Resilient Living program
Wear a FitBit
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adherence to each prehabilitation component based on patient reported adherence (Cohorts 2 & 3)
Time Frame: Weekly up to 4 months
|
Assessed based on patient reported adherence in Cohort 2. For cohort 3, adherence will be documented in MyDataHelps® and monitored remotely by the study team on the Care Evolution platform®.
Participants will be evaluated weekly for compliance with the recommended exercise and nutrition and resilience interventions.
Documentation of adherence will be through online patient messages, phone call, or during in person visits, whichever the patient prefers
|
Weekly up to 4 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Implementation outcome
Time Frame: Up to 4 months
|
Ability to recruit to this type of study and perform assessments at our institution will be measured based on the number of patients enrolled and the number of assessments completed throughout the study.
|
Up to 4 months
|
Difference in Short Physical Performance Battery (SPPB) at baseline between cohorts 1 and 2
Time Frame: Baseline
|
Short Physical Performance Battery (SPPB) will be measured at baseline in both cohorts.
|
Baseline
|
Change of Short Physical Performance Battery (SPPB) over time in cohort 2
Time Frame: Up to 4 months
|
The Short Physical Performance Battery (SPPB) assessment will be administered and scored at baseline and at each study visit to assess lower extremity functioning (balance, gait, standing up from a chair).
|
Up to 4 months
|
Correlation of Short Physical Performance Battery (SPPB) to other assessments in cohorts 1 and 2
Time Frame: Baseline, up to 4 months
|
The following assessment tools will be completed at baseline, after chemotherapy/prior to surgery (cohort 2), 6 weeks post surgery (cohort 2), and after completion of all primary anti-cancer treatment (cohort 2): Short Physical Performance Battery (SPPB); gait speed (measured in meters/second); patient reported outcomes through Patient-Reported Outcomes Measurement Information System (PROMIS) short form surveys in the domains of pain, physical function, anxiety, emotional support, and fatigue; perceived stress scale; Fried Frailty index; body composition measurements on CT scans performed for clinical purposes; serum collection for frailty biomarker; and Mindfulness Attention awareness scale.
|
Baseline, up to 4 months
|
Correlation of assessments to compliance with interventions in cohort 2
Time Frame: Baseline, up to 4 months
|
The following assessment tools will be completed at baseline, after chemotherapy/prior to surgery (cohort 2), 6 weeks post surgery (cohort 2), and after completion of all primary anti-cancer treatment (cohort 2): Short Physical Performance Battery (SPPB); gait speed (measured in meters/second); patient reported outcomes through Patient-Reported Outcomes Measurement Information System (PROMIS) short form surveys in the domains of pain, physical function, anxiety, emotional support, and fatigue; perceived stress scale; Fried Frailty index; body composition measurements on CT scans performed for clinical purposes; serum collection for frailty biomarker; and Mindfulness Attention awareness scale.
|
Baseline, up to 4 months
|
Correlation of frailty assessments with clinical judgement of frailty
Time Frame: Baseline, up to 4 months
|
The following assessments will be completed at baseline, after chemotherapy/prior to surgery (cohort 2), 6 weeks post surgery (cohort 2), and after completion of all primary anti-cancer treatment (cohort 2): Fried Frailty index; body composition measurements on CT scans performed for clinical purposes; serum collection for frailty biomarker; and Mindfulness Attention awareness scale.
Results from these will be compared for correlation.
|
Baseline, up to 4 months
|
Correlation of body composition on computed tomography (CT) scans to frailty assessments
Time Frame: Baseline, up to 4 months
|
The following assessments will be completed at baseline, after chemotherapy/prior to surgery (cohort 2), 6 weeks post surgery (cohort 2), and after completion of all primary anti-cancer treatment (cohort 2): Fried Frailty index; body composition measurements on CT scans performed for clinical purposes; serum collection for frailty biomarker; and Mindfulness Attention awareness scale.
Results from these will be compared for correlation.
|
Baseline, up to 4 months
|
Qualitative outcomes of the facilitators, barriers, perceived benefits, and burdens
Time Frame: Baseline, up to 4 months
|
Qualitative data from weekly contacts and exit interviews will be analyzed for codes and organized in themes to elucidate barriers, facilitators, perceived benefits, and negative effects of the program.
|
Baseline, up to 4 months
|
Acceptability of remote setting in Cohort 3
Time Frame: 30 days
|
Assessed using an Acceptability Questionnaire, which consists of 6 questions answered on a scale of 1-10 where 1=not at all and 10=extremely.
|
30 days
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Amanika A. Kumar, M.D., Mayo Clinic in Rochester
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Peritoneal Diseases
- Genital Neoplasms, Female
- Endocrine System Diseases
- Ovarian Diseases
- Adnexal Diseases
- Gonadal Disorders
- Digestive System Neoplasms
- Endocrine Gland Neoplasms
- Fallopian Tube Diseases
- Abdominal Neoplasms
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Genital Diseases
- Genital Diseases, Female
- Ovarian Neoplasms
- Fallopian Tube Neoplasms
- Peritoneal Neoplasms
- Carcinoma, Ovarian Epithelial
Other Study ID Numbers
- 21-005226
- NCI-2021-09494 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stage IIIC Fallopian Tube Cancer AJCC v8
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)WithdrawnStage III Fallopian Tube Cancer AJCC v8 | Stage III Ovarian Cancer AJCC v8 | Stage III Primary Peritoneal Cancer AJCC v8 | Stage IIIA Fallopian Tube Cancer AJCC v8 | Stage IIIA Ovarian Cancer AJCC v8 | Stage IIIA Primary Peritoneal Cancer AJCC v8 | Stage IIIA1 Fallopian Tube Cancer AJCC v8 | Stage... and other conditionsUnited States
-
Precigen, IncRecruitingRecurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Platinum-Resistant Ovarian Carcinoma | Refractory Ovarian Carcinoma | Stage III Fallopian Tube... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingBRCA1 Gene Mutation | BRCA2 Gene Mutation | Primary Peritoneal High Grade Serous Adenocarcinoma | Stage III Fallopian Tube Cancer AJCC v8 | Stage III Ovarian Cancer AJCC v8 | Stage III Primary Peritoneal Cancer AJCC v8 | Stage IIIA Fallopian Tube Cancer AJCC v8 | Stage IIIA Ovarian Cancer AJCC v8 | Stage... and other conditionsUnited States
-
Ohio State University Comprehensive Cancer CenterRecruitingOvarian Endometrioid Adenocarcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube Endometrioid Adenocarcinoma | Fallopian Tube Mucinous Adenocarcinoma | Fallopian Tube Serous Adenocarcinoma | Ovarian Serous Adenocarcinoma | Primary Peritoneal Serous Adenocarcinoma | Primary Peritoneal Endometrioid... and other conditionsUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)Active, not recruitingMetastatic Melanoma | Advanced Malignant Solid Neoplasm | Unresectable Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Pathologic Stage IIID Cutaneous Melanoma AJCC v8 | Pathologic Stage... and other conditionsUnited States
-
M.D. Anderson Cancer CenterRecruitingMalignant Solid Neoplasm | Metastatic Renal Cell Carcinoma | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC v8 | Prognostic Stage III Breast Cancer AJCC v8 | Prognostic Stage... and other conditionsUnited States
-
Pamela MunsterPfizer; Xynomic Pharmaceuticals, Inc.WithdrawnAnatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC v8 | Prognostic Stage III Breast Cancer AJCC v8 | Prognostic Stage IIIA Breast Cancer AJCC v8 | Prognostic Stage IIIB Breast... and other conditions
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingOvarian Endometrioid Adenocarcinoma | Ovarian Clear Cell Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian Transitional Cell Carcinoma | Fallopian Tube Clear Cell Adenocarcinoma | Ovarian Serous Adenocarcinoma | Primary Peritoneal Serous Adenocarcinoma | Primary Peritoneal Clear... and other conditionsUnited States
-
NRG OncologyNational Cancer Institute (NCI)RecruitingStage III Fallopian Tube Cancer AJCC v8 | Stage III Ovarian Cancer AJCC v8 | Stage III Primary Peritoneal Cancer AJCC v8 | Stage IV Fallopian Tube Cancer AJCC v8 | Stage IV Ovarian Cancer AJCC v8 | Stage IV Primary Peritoneal Cancer AJCC v8 | Stage II Fallopian Tube Cancer AJCC v8 | Stage II Ovarian... and other conditionsUnited States, Korea, Republic of, Canada, Puerto Rico
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingRecurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Endometrial Carcinoma | Stage IV Uterine Corpus Cancer AJCC v8 | Stage IVA Uterine Corpus Cancer AJCC v8 | Stage IVB Uterine Corpus Cancer AJCC v8 | Recurrent Cervical Carcinoma | Malignant... and other conditionsUnited States
Clinical Trials on Survey Administration
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)TerminatedHealth Status UnknownUnited States
-
Centre Oscar LambretCentre Hospitalier Universitaire de BesanconTerminated
-
Boston UniversityNational Heart, Lung, and Blood Institute (NHLBI)Completed
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)RecruitingAcute Lymphoblastic LeukemiaUnited States
-
M.D. Anderson Cancer CenterRecruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditionsUnited States
-
M.D. Anderson Cancer CenterActive, not recruitingHematopoietic and Lymphoid Cell Neoplasm | Advanced Malignant Solid Neoplasm | Locally Advanced Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | COVID-19 Infection | Recurrent Hematologic MalignancyUnited States
-
Thomas Jefferson UniversityNational Cancer Institute (NCI)CompletedHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedPancreatic Adenocarcinoma | Gastric Adenocarcinoma | Pancreatic Neuroendocrine CarcinomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedMalignant NeoplasmUnited States